Is Surgical Cytoreduction for Stage IV Pancreatic Neuroendocrine Tumors Justifiable?

Yi-Zarn Wang MD FACS¹ Elizabeth McCord BS¹, David Beyer, BS¹, Melissa Aycock Stevens MPH¹, J. Philip Boudreaux MD FACS¹, Robert Ramirez DO FACP², Anne E. Diebold BS², Eugene A. Woltering MD FACS¹

¹Louisiana State University Health Sciences Center, Department of Surgery, New Orleans, LA, ²Ochsner Medical Center – Kenner, Neuroendocrine Tumor Program, Kenner, LA

Background

Pancreatic neuroendocrine tumors (pNETs) comprise <2% of all pancreatic tumors. They can be present as functioning or non-functioning tumors. Long-term survival in patients with metastatic disease is generally poor, with recent Surveillance, Epidemiology, and End Results (SEER) data demonstrating 5- and 10-year survival rates of 19.5% and 7.1%, respectively.

Hypothesis

We hypothesize that surgical cytoreduction is beneficial for patients with stage IV pancreatic neuroendocrine tumors.

Methods

A database consisting of all patients seen at the Neuroendocrine Tumor Program (LSU/Ochsner Medical Center-Kenner) was queried for well-differentiated neuroendocrine tumors of the pancreas diagnosed between May 2006 and July 2012. Of the eighty-nine patients that fit this criteria, only the patients with pathologically confirmed liver metastasis were included for analysis (n=64/89, 72%). Tumor characteristics and surgical procedures were extracted and reviewed. Kaplan-Meier survival curves were generated and analyzed via MedCalc® Version 15.8.

Results

Sixty-four patients with pathologically confirmed metastatic pancreatic neuroendocrine tumor were included for analysis. Fifty-one patients (51/64, 80%) had non-functional pNETs and thirteen (13/64, 20%) had functional pNETs. Sixteen patients (16/64, 25%) had their primary pancreatic NET resected without simultaneous liver resection, while twenty-seven patients (27/64, 42%) underwent resection of both their primary pancreatic tumor and liver metastasis. Five patients (5/64, 8%) had only their liver metastasis surgically removed. The remainder of patients in this study (16/64, 25%) did not undergo any NET-related surgical procedure.

The survival analysis for the entire cohort is shown in the table below.

<table>
<thead>
<tr>
<th>Kaplan-Meier Survival Analysis</th>
<th>Surgical Group (N=48/64, 75%)</th>
<th>Non-Surgical Group (N=16/64, 25%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median Survival</td>
<td>81 months</td>
<td>61 months</td>
</tr>
<tr>
<td>5-year Survival Rate</td>
<td>66%</td>
<td>54%</td>
</tr>
<tr>
<td>10-year Survival Rate</td>
<td>49%</td>
<td>45%</td>
</tr>
</tbody>
</table>

Although our results proved not to be statistically significant, there is a survival advantage seen in the group who elected to have surgery. Therefore, we recommend aggressive surgical cytoreduction for patients with stage IV pancreatic neuroendocrine tumors for those who are low-risk surgical candidates. Further prospective studies are required to determine the efficacy of surgical cytoreduction in stage IV pNETs.